dezapelisib
Generic: Dezapelisib
dezapelisib: 1 clinical trial tracked.
dezapelisib evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about dezapelisib, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1, Open-label, Dose Escalation, Safety and Tolerability Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
Primary endpoint: Safety and tolerability of INCB040093 as monotherapy and when given in combination with itacitinib as determined by clinical laboratory assessments, physical exams, 12-lead ECG and summary of adverse events
Interventionalopen121 enrolledStarted 2013-06Completion 2026-026 sites · United StatesIncyte Corporation